腫瘤蛋白53抗體/p53 Antibody |
|
|
產(chǎn)品名稱 ： 腫瘤蛋白53抗體/p53 Antibody
產(chǎn)品類別 ： IVD診斷抗體原料
品 牌 ： GenomeMe
貨 號 ： IHC053
規(guī) 格 ： 0.1ml/1ml
|
|
詳細(xì)信息 |
|
|
純化方式 ：
緩 沖 液 ：
應(yīng)用說明 ：
形 態(tài) ：
產(chǎn)品說明 ：
背景描述Description：
p53又稱腫瘤蛋白53(TumorProtein53，TP53)，是一種腫瘤抑制因子和轉(zhuǎn)錄因子，在DNA損傷或其他應(yīng)激源引起的細(xì)胞凋亡、DNA修復(fù)、細(xì)胞周期阻滯等多種抗癌活動中發(fā)揮重要作用。p53的突變與許多惡性腫瘤有關(guān)，包括乳腺、卵巢、膀胱、結(jié)腸、肺和黑色素瘤。抗p53染色已用于檢測腎小管內(nèi)生殖細(xì)胞腫瘤，并用于區(qū)分子宮漿液性癌和子宮內(nèi)膜樣癌。
p53, also known as tumor protein 53 or TP53, is a tumor suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumors, including those of the breast, ovarian, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
Specifications:
Clone IHC053
Source Mouse Monoclonal
Positive Control Colon Carcinoma
Dilution Range 1:50-1:200
參考文獻(xiàn)References：
Stoehlmacker J, et al. Oncol. 2003; 30:10-16.
Gallo O, et al. Hum Pathol. 2002; 33:708-714.
Sano H, et al. Cancer Res. 1995: 55:3785-9.
Denkert C, et al. Cancer. 2003; 97:2978-87.
Sheehan KM, et al. Hum Pathol. 2003; 34:1242-1246.
Moore BE, et al. Appl Immunohistochem Mol Morphol. 2001; 9:203-6.
Mauri FA, et al. Int J Oncol. 1999; 15:1137-47.
Caffo O, et al. Clin Cancer Res. 1996; 2:1591-9.
Bebenek M, et al. Anticancer Res. 1998; 18:619-23.
Midulla C, et al. Anticancer Res. 1999; 19:4033-7.
Zen ZS, et al. J Clin Oncol. 1994; 12:2043-50.
Quinlan DC, et al. Cancer Res. 1992; 53:4828-31.
Alexiev BA, et al. Gen Diagn Pathol. 1997; 142:271-9.
Liang Y, et al. Arch Dermatol Res. 1999; 291:14-21.
|
|
| {返回} | |
| |||||||||||
